BioVie Inc. (NASDAQ:BIVI) Short Interest Update

BioVie Inc. (NASDAQ:BIVI) was the target of a significant growth in short interest in the month of October. As of October 31st, there was short interest totalling 1,920,000 shares, a growth of 922.9% from the October 15th total of 187,700 shares. Currently, 35.0% of the shares of the company are sold short. Based on an average daily volume of 5,160,000 shares, the short-interest ratio is currently 0.4 days.

Hedge Funds Weigh In On BioVie

An institutional investor recently raised its position in BioVie stock. Sheaff Brock Investment Advisors LLC grew its position in shares of BioVie Inc. (NASDAQ:BIVI) by 276.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 51,400 shares of the company’s stock after purchasing an additional 37,762 shares during the period. Sheaff Brock Investment Advisors LLC owned approximately 0.13% of BioVie worth $27,000 at the end of the most recent quarter. 4.59% of the stock is currently owned by institutional investors and hedge funds.

BioVie Stock Up 12.0 %

Shares of BioVie stock traded up $0.36 on Tuesday, hitting $3.35. The stock had a trading volume of 4,736,990 shares, compared to its average volume of 1,654,124. BioVie has a twelve month low of $1.04 and a twelve month high of $58.20. The stock has a market cap of $31.26 million, a price-to-earnings ratio of -0.25 and a beta of 0.40. The business’s 50 day moving average is $2.19 and its two-hundred day moving average is $1.39.

BioVie (NASDAQ:BIVI) last posted its earnings results on Monday, September 30th. The company reported ($6.60) earnings per share for the quarter.

BioVie Company Profile

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.